AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
In this recent article published in the journal Neurology, scientists in Netherlands conducted a study "To assess which baseline clinical and MRI measures influence whole-brain atrophy rates, measured from serial MR imaging. We recruited 65 patients with Alzheimer disease (mean +/- SD age 70 +/- 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 +/- 5), scanned with an average interval of 1.7 +/- 0.6 years."
"Whole-brain atrophy rates were used as outcome measure. Baseline normalized brain volume, hippocampal volume, and whole-brain atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized brain volume on whole-brain atrophy rates was assessed using linear regression. The mean whole-brain atrophy rate was -1.9 +/- 0.9% per year. In the multivariate model, younger age (beta [SE] = 0.03 [0.01]; p = 0.04), absence of APOE epsilon 4 (beta[SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (beta [SE] = 0.11 [0.03]; p
The researchers concluded: "Patients with more generalized, rather than focal hippocampal atrophy, who often have an onset before the age of 65, and are APOE epsilon 4 negative, seem to be at risk of faster whole-brain atrophy rates than the more commonly seen patients with AD, who are older, are APOE epsilon 4 positive, and have ...
Source: HighBeam Research, Studies from Vrije University Amsterdam add new findings in the area...